Nuvalent, Inc.
zidesamtinib
ROS1-positive NSCLC
Countdown
177days
Catalyst readout · ~ Dec 31, 2026 estimated
What's at stake
A key catalyst for zidesamtinib (ROS1-positive NSCLC) is expected ~ Dec 31, 2026.
Primary source
· SEC 8-K
verified 15h ago
“Submission for potential indication expansion of zidesamtinib in TKI-naïve advanced ROS1-positive NSCLC population planned for the second half of 2026”